Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 AlteredExpression disease BEFREE The expression of circ-DB and MET in GCa tissues was significantly higher than that in the corresponding adjacent tissues. 31799656 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE Inactivation of CDH1 and RARB by DNA hypermethylation, and amplification of FGFR and MET, are frequently detected in diffuse type GC. 30980196 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE This article reports a case of c-MET gene amplification in advanced gastric cancer with liver metastases. 31499745 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 AlteredExpression disease BEFREE Volumetric parameters on <sup>18</sup>F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET. 31395059 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer. 30511201 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE In 123 cases with primary and corresponding local recurrent/distant metastatic GC, 3 (2.4%) showed MET positivity in which 2 (66.7%) were discordant (positive conversion). 28968267 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 AlteredExpression disease BEFREE MET amplification and Met overexpression were positively correlated in GC. 29790169 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE MACC1, a transcriptional regulator of MET, was recognized as an oncogene in gastric cancer (GC); however, its transcriptional or post-translational regulation was not clear. 29510730 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE Four c-MET inhibitors were tested to elucidate the dependency on MET pathway in the 49 GC cell lines. 29435981 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE MACC1, HGF and c-Met might cooperatively participate in the malignant progression of gastric cancer. 29435059 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 AlteredExpression disease BEFREE MiR-658, paired box gene 3 (PAX3) and met proto-oncogene (MET) are overexpressed in gastric cancer while PAX3 and MET can be regulated by miRNA. 29630524 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE In vivo experiments revealed that CAFs-derived HGF promoted tumorigenesis and metastasis of MET-unamplified GC. 30158543 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 GeneticVariation disease BEFREE Overall, our results indicate that prolonged MAPK pathway inhibition could result in acquired resistance which is associated with increased malignant phenotype in KRAS mutant GC and pharmacological targeting c-MET and PI3K/mTOR could overcome this problem. 30466782 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE Therefore, MET overexpression could serve as a prognostic biomarker and a potential therapeutic target for gastric cancer. 28052014 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 AlteredExpression disease BEFREE We then analyzed MET expression and activity in a matched set of FFPE vs. fresh frozen tumor samples consisting of 20 cases of gastric cancer. 28836864 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE MET amplification has been clinically credentialed as a therapeutic target in gastric cancer, but the molecular mechanisms underlying sensitivity and resistance to MET inhibitors are still not well understood. 28881678 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE This study describes the prevalence and prognostic value of EGFR and c-MET in a Canadian population of patients undergoing curative intent resection for GC. 26125303 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer. 28314274 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE A multivariate analysis suggested that MET positivity may still be prognostic for worse median overall survival in gastric cancer; therefore, it is important to continue investigation into the optimal approach to inhibit MET signaling in gastric cancer. 27401892 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE Similar results were obtained in additional GC cell lines with amplification of MET or the FGF receptor FGFR2 MKN45 murine xenograft experiments demonstrated the antitumor activity of M-COPA in vivo Taken together, our results offer an initial preclinical proof of concept for the use of M-COPA as a candidate treatment option for MET-addicted GC, with broader implications for targeting the Golgi apparatus as a novel cancer therapeutic approach. 27197184 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. 27437872 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE Crizotinib may induce clinically relevant anticancer effects in MET-overexpressed or MET-amplified gastric cancer patients. 26404902 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE MET-positive GCs had a very poor prognosis, with a median survival of 5.4 months and a hazard ratio of 2.126. 26033401 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE Overexpression of MET occurs frequently in gastric cancer and has been proposed as a potential predictive biomarker for anti-MET therapy. 26690587 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.700 Biomarker disease BEFREE Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer. 27185371 2016